

Date 02/06/2026
Your Ref
Our Ref 11454

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – CANCER PRESCRIBING

I write in response to your request for information in relation to cancer prescribing.

Question:

1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period available?

Answer:

Abemaciclib (Verzenios) = 44
Alpelisib (Piqray) = 0
Elaeostanol (Orserdu) = 0
Fulvestrant (fulvestrant or Faslodex) = 49
Inavolisib (Inaqovi) = 0
Palbociclib (Ibrance) = 22
Ribociclib (Kisqali) = 47
Capivasertib (Truqap) = 0
Talazoparib (Talzenna) = 0
Olaparib (Lynparza) = 18

Question:

2. How many patients received the following medicines for early breast cancer in the 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period for which data are available?

Answer:

Abemaciclib (Verzenios) = Data unavailable - requires linkage
Ribociclib (Kisqali) = Data unavailable - requires linkage
Olaparib (Lynparza) = Data unavailable - requires linkage

Headquarters
Mainpoint
102 West Port
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
Chief Executive Professor Caroline Hiscox
*Lothian NHS Board is the common
name of Lothian Health Board*

This information is not held in a centrally extractable format. Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

Question:

3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period for which data are available?

Answer:

Abemaciclib (Verzenios) = 36
Ribociclib (Kisqali) = 5 or fewer

Question:

4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period available?

Answer:

Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex) = 5 or fewer
Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex) = 9
Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex) = 18
Inavolisib (Inaqovi) + Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex) = 0

This information is exempt under Section 25 of the Freedom of Information (Scotland) Act 2002 - Information otherwise accessible

(1) Information which the applicant can reasonably obtain other than by requesting it under section 1(1) is exempt information.

Question:

5. How many patients were treated specifically for breast cancer in the 3 months between the start of January 2026 and the end of March 2026?

Answer:

Olaparib - All types of breast cancer = 7
Olaparib - Locally advanced or metastatic breast cancer = Data unavailable - requires linkage
Talazoparib – All types of breast cancer = 0

To protect the identity of the individuals involved any figure of 5 or less has not been shown in this response. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

Question:

6. How many Endometrial Cancer (C54.1) patients by subtype deficient mismatch repair (dMMR) and proficient mismatch repair (pMMR) are treated with the following within the last 3 months between the start of January 2026 and the end of March 2026, or latest 3-month period for which data are available?

Answer:

Dostarlimab + Carboplatin + Paclitaxel = Data unavailable - requires linkage
Pembrolizumab + Carboplatin + Paclitaxel = Data unavailable - requires linkage
Pembrolizumab + Lenvatinib = Data unavailable - requires linkage
Dostarlimab as monotherapy at cycle 1 = Data unavailable - requires linkage
Dostarlimab as monotherapy maintenance (cycle 7+) = Data unavailable - requires linkage
Pembrolizumab as monotherapy at cycle 1 = Data unavailable - requires linkage
Pembrolizumab as monotherapy maintenance (cycle 7+) = Data unavailable - requires linkage
Durvalumab + Carboplatin + Paclitaxel = Data unavailable - requires linkage
Durvalumab + Carboplatin + Paclitaxel + Olaparib (Poly ADP-ribose Polymerase Inhibitor) - Data unavailable - requires linkage

Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files relating to patients over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.



If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive